Ifrah Financial Services Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 63.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,787 shares of the biopharmaceutical company’s stock after purchasing an additional 2,631 shares during the period. Ifrah Financial Services Inc.’s holdings in Gilead Sciences were worth $550,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Hanson & Doremus Investment Management raised its holdings in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences during the second quarter worth approximately $147,000. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares in the last quarter. Rowland & Co. Investment Counsel ADV bought a new position in shares of Gilead Sciences in the second quarter valued at $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new position in shares of Gilead Sciences in the second quarter valued at $172,000. 75.94% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.02 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The stock has a market cap of $103,221.38, a price-to-earnings ratio of 8.25, a price-to-earnings-growth ratio of -1.68 and a beta of 1.13.
The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.63%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.
In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the transaction, the insider now owns 3,070,099 shares in the company, valued at $230,656,537.87. The disclosure for this sale can be found here. Over the last three months, insiders have sold 461,666 shares of company stock worth $34,072,567. Company insiders own 1.30% of the company’s stock.
Several research firms have issued reports on GILD. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Oppenheimer began coverage on Gilead Sciences in a report on Thursday, October 5th. They issued a “market perform” rating on the stock. Mizuho upped their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Leerink Swann upped their price target on Gilead Sciences from $87.00 to $89.00 and gave the company a “market perform” rating in a report on Thursday, October 5th. Finally, BMO Capital Markets dropped their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $85.03.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (GILD) Position Raised by Ifrah Financial Services Inc.” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.com-unik.info/2018/01/14/gilead-sciences-inc-gild-position-raised-by-ifrah-financial-services-inc.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.